Benitec Biopharma Inc. Capital Expenditures
Benitec Biopharma Inc. (BNTC) reported Capital Expenditures of $105.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-09-14
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $79.00K.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $15.00K, a 150.00% increase year-over-year.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $0.00.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $6.00K.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2026 was $105.00K, a 483.33% increase from fiscal 2025.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $18.00K, a 89.94% decline from fiscal 2024.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $179.00K, a 17800.00% increase from fiscal 2023.
- Benitec Biopharma Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.00K, a 92.31% decline from fiscal 2022.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $94.00K derived: sum of 2 quarters · filed 2026-09-14 | $105.00K 10-K · filed 2026-09-14 | |
| 2026-03-31 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $26.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $11.00K 10-Q · filed 2026-02-12 | |||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | $6.00K derived: sum of 2 quarters · filed 2026-09-14 | $18.00K 10-K · filed 2026-09-14 | |
| 2025-03-31 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | $18.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $12.00K 10-Q · filed 2026-02-12 | |||
| 2024-06-30 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | $179.00K 10-K/A · filed 2026-03-20 | ||
| 2024-03-31 | $179.00K 10-Q · filed 2025-05-14 | |||
| 2023-06-30 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $1.00K 10-K · filed 2024-09-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | |||
| 2022-06-30 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | $13.00K derived: sum of 2 quarters · filed 2023-09-21 | $13.00K derived: sum of 3 quarters · filed 2023-09-21 | $13.00K 10-K · filed 2023-09-21 |
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2022-05-16 | $0.00 10-Q · filed 2022-05-16 | -$141.00K derived: sum of 4 quarters · filed 2022-09-02 |
| 2021-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $0.00 10-Q · filed 2022-02-14 | -$141.00K derived: sum of 3 quarters · filed 2022-09-02 | -$126.00K derived: sum of 4 quarters · filed 2022-09-02 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | -$141.00K derived: sum of 2 quarters · filed 2022-09-02 | -$126.00K derived: sum of 3 quarters · filed 2022-09-02 | $48.00K derived: sum of 4 quarters · filed 2022-09-02 |
| 2021-06-30 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | -$126.00K derived: sum of 2 quarters · filed 2022-09-02 | $48.00K derived: sum of 3 quarters · filed 2022-09-02 | $221.00K 10-K · filed 2022-09-02 |
| 2021-03-31 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $189.00K derived: sum of 2 quarters · filed 2022-05-16 | $362.00K 10-Q · filed 2022-05-16 | $375.00K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $347.00K 10-Q · filed 2022-02-14 | $360.00K derived: sum of 3 quarters · filed 2022-02-14 | $360.00K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $173.00K 10-Q · filed 2021-11-15 | $186.00K derived: sum of 2 quarters · filed 2021-11-15 | $186.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | $13.00K derived: sum of 2 quarters · filed 2021-09-20 | $95.00K 10-K · filed 2021-09-20 | |
| 2020-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-12 | $82.00K 10-Q · filed 2021-05-12 | ||
| 2019-12-31 | $82.00K 10-Q · filed 2021-02-09 | |||
| 2019-06-30 | $404.00K 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |